Lupin has received approval from China’s National Medical Products Administration for its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, a leader in China’s paediatric medicine market. This marks the company’s first product entry into China - a significant step in its global expansion.
Oseltamivir Phosphate for oral suspension, 6 mg/mL will be launched and commercialized to expand access, particularly for paediatric use. This expands the company’s global footprint and its commitment to delivering high-quality, affordable medicines to patients and children in need. Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL is indicated for treatment of influenza A and B in patients 2 weeks of age and older; and for prevention of influenza A and B in individuals 1 year of age and older.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
